Since 2017, novel variant strains of infectious bursal disease virus (nvIBDV) have been detected in China, while the current vaccines against very virulent IBDV (vvIBDV) on the markets have limited protection against this subtype virus. In this context, a strain of the virus has been isolated, and sequencing alignment and animal regression experiments showed that the strain of the virus is IBDV, belonging to the nvIBDV subtype (and named IBDV FJ-1812). Furthermore, the E. coli expression system was used to successfully express soluble nvIBDV rVP2, which is specifically recognized by an anti-IBDV standard serum and anti-nvIBDV positive serum, and could be assembled into 14−17 nm virus-like particles. Based on the purified nvIBDV rVP2, we developed an IBDV FJ-1812 VP2 VLP vaccine at a laboratory scale to evaluate this vaccine protection; in addition, we also prepared an IBDV JZ 3/02 VP2 subunit vaccine targeting vvIBDV and evaluated its cross-protection against nvIBDV. Animal experiments results showed that the nvIBDV rVP2 vaccine could induce high titers of specific antibodies, completely protect the bursa of Fabricius from viral infection, and provide 100% immune protection to SPF and Rose 308 Broiler chickens; furthermore, the IBDV JZ 3/02 VP2 subunit vaccine targeting vvIBDV could provide 60% protection for SPF chickens and 80% protection for Rose 308 Broiler chickens. This report provides important technical supports for the prevention and control of nvIBDV in the future.
The Cap of porcine circovirus type 2 (PCV2) can be assembled into virus like particles (VLPs) in vitro that have multiple loops located on the particle surface. This would make it a good vehicle for displaying exogenous proteins or epitopes. We derived two epitopes, epitope B (EpB, S37HIQLIYNL45) and epitope 7 (Ep7, Q196WGRL200) from Gp5 of the highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV). We replaced the core region of Loop CD (L75PPGGGSN82) and the carboxyl terminus (K222DPPL226) of PCV2 Cap, respectively, to construct a bi-epitope chimeric PCV2 Cap. Its immunogenicity and protective effects were evaluated as one PRRSV subunit vaccine. The chimeric PCV2 Cap was soluble, efficiently expressed in an Escherichia coli expression system, and could be self-assembled into chimeric virus like particles (cVLPs) with a diameter of 12–15 nm. Western blotting confirmed that the cVLPs could be specifically recognized by anti-PCV2, anti-EpB and anti-Ep7 antibodies. The cVLPs vaccine could alleviate the clinical symptoms and reduce the viral loads after HP-PRRSV challenge in 100-120 days old pigs. These data suggest that the cVLPs vaccine could provide pigs with partial protection against homologous PRRSV strains, and it provides a new design for additional PRRSV subunit vaccines.
Introduction. PCV2 is a DNA virus that exists widely in pigs and has caused great economic losses to the pig industry worldwide. In the existing commercial PCV2 enzyme-linked immunosorbent assay (ELISA) kits both natural infection with PCV2 and vaccine immunization produce results that are positive for PCV2 Cap antibodies and therefore they cannot diagnose PCV2 infection in immunized pig farms. Aim. To establish a PCV2 non-structural protein antibody detection method that distinguishes between antibodies resulting from natural prior exposure (infection) and those induced by subunit vaccine immunization. Methodology. Based on the non-structural Rep' protein, we established an indirect ELISA (iELISA) using sera from guinea pigs and piglets. Results. The results for iELISA for guinea pig serum showed that animals vaccinated with a whole-virus inactivated PCV2 vaccine had 100 % (10/10) Cap antibody positivity and 100% (10/10) Rep' antibody positivity. Guinea pigs vaccinated with a recombinant subunit PCV2 vaccine had 100 % (10/10) Cap antibody positivity, while no (0/10) guinea pigs were Rep' antibody-positive. The combined detection results for the Rep' iELISA and a PCV2 Antibody Test kit (Commercial) showed that pigs vaccinated with a whole-virus inactivated PCV2 vaccine or PCV2 SD/2017 had 100% (5/5) Cap antibody positivity and 100% (5/5) Rep' antibody positivity. Pigs vaccinated with a recombinant subunit PCV2 vaccine had 100 % (5/5) Cap antibody positivity, while no (0/10) pigs were Rep' antibody-positive. Conclusion. This paper describes an effective iELISA method that can distinguish natural infection with PCV2 (Cap and Rep positive) or inoculation with a whole-virus inactivated vaccine (Cap and Rep positive) from subunit vaccine immunization (Cap-positive, Rep-negative). These comparative assays could be very useful in the control of PCV2 in pig herds.
Fowl adenovirus serotype 11 (FAdV-11) is an emerging pathogen associated with inclusion body hepatitis (IBH) and high mortality in commercial broilers. In this study, we evaluated the protective efficacy of maternal antibody transfer against FAdV-11 in neonatal chicks. A hypervirulent FAdV-11 strain (FAdV-11/HB2022/1), isolated from an IBH outbreak in Hubei Province, China, caused 90% mortality in 1-day-old specific-pathogen-free (SPF) chickens; 7-day-old chicks exhibited no mortality but developed mild hepatic lesions and sustained viral replication. A soluble, trimeric Fiber subunit vaccine (Fiber282–569) was developed through rational truncation of the transmembrane domain, retaining both the shaft and head domains, with its homotrimeric conformation confirmed by size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS). Immunization of breeder hens with Fiber282–569 elicited high titers of FAdV-11-specific IgY and neutralizing antibodies that were efficiently transferred to progeny via the egg yolk. Upon lethal challenge with FAdV-11/HB2022/1, 1-day-old progeny chicks from vaccinated breeders exhibited 100% survival with no clinical signs, no gross pathological lesions, and undetectable viral loads in liver tissues, demonstrating complete protection. In contrast, all chicks from unvaccinated breeders succumbed within 5 days post-infection. These results demonstrate that maternal antibody transfer of the fiber-based subunit vaccine confers complete protection against lethal FAdV-11 infection in neonatal chicks, providing a safe and effective candidate strategy for controlling FAdV-11 in the poultry industry.